These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1112 related items for PubMed ID: 15545527

  • 21. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
    Belenkov IuN, Mareev VIu, Skvortsov AA.
    Ter Arkh; 2008; 80(9):5-12. PubMed ID: 19555028
    [No Abstract] [Full Text] [Related]

  • 22. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A, Battegay E.
    Praxis (Bern 1994); 2005 Apr 13; 94(15):581-94. PubMed ID: 15884724
    [Abstract] [Full Text] [Related]

  • 23. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK, Epstein M.
    Clin J Am Soc Nephrol; 2006 Sep 13; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract] [Full Text] [Related]

  • 24. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 13; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 25. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT, Greenberg BH, Yancy CW.
    Am J Cardiol; 2008 Sep 08; 102(5A):21G-28G. PubMed ID: 18722188
    [Abstract] [Full Text] [Related]

  • 26. Should angiotensin II receptor blockers and statins be combined?
    Nickenig G.
    Circulation; 2004 Aug 24; 110(8):1013-20. PubMed ID: 15326080
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
    Porcu M.
    Ital Heart J; 2002 Jul 24; 3(7):437-8. PubMed ID: 12189976
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cellular basis for therapeutic choices in heart failure.
    Opie LH.
    Circulation; 2004 Oct 26; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
    Scott RL.
    Cardiol Clin; 2008 Feb 26; 26(1):73-7, vii. PubMed ID: 18312907
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Kudo Y, Komuro I, Akazawa H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():84-9. PubMed ID: 17571370
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
    Ku E, Park J, Vidhun J, Campese V.
    Arch Intern Med; 2009 Jun 08; 169(11):1015-8. PubMed ID: 19506167
    [No Abstract] [Full Text] [Related]

  • 40. [Inhibition of renin-angiotensin-aldosterone system: what evidence?].
    Mota T.
    Rev Port Cardiol; 2001 Mar 08; 20 Suppl 3():13-5. PubMed ID: 11409069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.